Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $13.7850 (7.07%) ($13.1100 - $13.7900) on Mon. Sep. 14, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.54% (three month average) | RSI | 45 | Latest Price | $13.7850(7.07%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 0.2% a day on average for past five trading days. | Weekly Trend | FOLD declines -3.5% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(53%) IWO(50%) XBI(50%) IWM(47%) IWC(45%) | Factors Impacting FOLD price | FOLD will decline at least -1.77% in a week (0% probabilities). VIXM(-29%) VXX(-14%) UUP(-12%) UNG(-4%) IGOV(-4%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.77% (StdDev 3.54%) | Hourly BBV | 0.3 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $6.03(-56.26%) | Inflection Point | Yes | Resistance Level | $14.14 | 5 Day Moving Average | $13.48(2.26%) | 10 Day Moving Average | $13.73(0.4%) | 20 Day Moving Average | $14.14(-2.51%) | To recent high | -13.2% | To recent low | 23.7% | Market Cap | $3.56b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |